Search Results - "Meuth, S"

Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials by Ingwersen, J., Masanneck, L., Pawlitzki, M., Samadzadeh, S., Weise, M., Aktas, O., Meuth, S. G., Albrecht, P.

“…Ocrelizumab is a B cell-depleting drug widely used in relapsing–remitting multiple sclerosis (RRMS) and primary-progressive MS. In RRMS, it is becoming…”
Get full text

The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis by Willison, A. G., Ruck, T., Lenz, G., Hartung, H. P., Meuth, S. G.

“…Autologous haematopoietic stem cell transplantation (aHSCT) is gaining traction as a valuable treatment option for patients affected by severe multiple…”
Get full text

Stem cell transplantation and alemtuzumab – options for ‘early reprogramming’ in multiple sclerosis? by Pfeuffer, S., Meuth, S. G.

Get full text

Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis by Willison, A. G., Ruck, T., Lenz, G., Hartung, H. P., Meuth, S. G.

Get full text

Disease‐modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies by Melzer, N., Meuth, S. G.

“…Summary Multiple sclerosis (MS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) represent chronic, autoimmune demyelinating disorders of…”
Get full text

Multiple sclerosis: interventions to halt disease : Which patients can be considered for autologous stem cell transplantation by Willison, A G, Meuth, S G

“…Autologous hematopoietic stem cell transplantation (aHSCT) for treatment of multiple sclerosis (MS) is gaining increasing prominence in the therapeutic…”
Get full text

High socioeconomic impact on prescription behavior despite unrestricted access to disease-modifying therapies in people with multiple sclerosis by Samadzadeh, S, Havla, J, Lepka, K, Brinks, R, Meuth, S G, Klotz, L, Albrecht, P

“…Economic and health care restraints strongly impact on drug prescription for chronic diseases. We aimed to identify potential factors for prescription behavior…”
Get full text

Electrical pharyngeal stimulation increases substance P level in saliva by Suntrup‐Krueger, S., Bittner, S., Recker, S., Meuth, S. G., Warnecke, T., Suttrup, I., Marian, T., Dziewas, R.

“…Background Substance P (SP) is a neuropeptide known to enhance the swallow response. It likely acts as a neurotransmitter in the pharyngeal mucosa in response…”
Get full text

Early effective treatment may protect from cognitive decline in paediatric multiple sclerosis by Johnen, A., Elpers, C., Riepl, E., Landmeyer, N.C., Krämer, J., Polzer, P., Lohmann, H., Omran, H., Wiendl, H., Göbel, K., Meuth, S.G.

“…Cognitive impairment (CI) is a critical feature for patients with childhood or juvenile multiple sclerosis (MS). To promote the understanding of CI and to…”
Get full text

Essential Role of Brain-Derived Neurotrophic Factor in Adult Hippocampal Function by Monteggia, Lisa M., Barrot, Michel, Powell, Craig M., Berton, Olivier, Galanis, Victor, Gemelli, Terry, Meuth, Sven, Nagy, Andreas, Greene, Robert W., Nestler, Eric J., Bloom, Floyd E.

“…Brain-derived neurotrophic factor (BDNF) regulates neuronal development and function. However, it has been difficult to discern its role in the adult brain in…”
Get full text

Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination by Choi, E Y, Lim, J-H, Neuwirth, A, Economopoulou, M, Chatzigeorgiou, A, Chung, K-J, Bittner, S, Lee, S-H, Langer, H, Samus, M, Kim, H, Cho, G-S, Ziemssen, T, Bdeir, K, Chavakis, E, Koh, J-Y, Boon, L, Hosur, K, Bornstein, S R, Meuth, S G, Hajishengallis, G, Chavakis, T

“…Inflammation in the central nervous system (CNS) and disruption of its immune privilege are major contributors to the pathogenesis of multiple sclerosis (MS)…”
Get full text

Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review by Ziemssen, T, Rauer, S, Stadelmann, C, Henze, T, Koehler, J, Penner, I-K, Lang, M, Poehlau, D, Baier-Ebert, M, Schieb, H, Meuth, S

“…So far, clinical studies in primary progressive MS (PPMS) have failed to meet their primary efficacy endpoints. To some extent this might be attributable to…”
Get full text

Reliability and main findings of the flexible endoscopic evaluation of swallowing‐Tensilon test in patients with myasthenia gravis and dysphagia by Im, S., Suntrup‐Krueger, S., Colbow, S., Sauer, S., Claus, I., Meuth, S. G., Dziewas, R., Warnecke, T.

“…Background and purpose Diagnosis of pharyngeal dysphagia caused by myasthenia gravis (MG) based on clinical examination alone is often challenging. Flexible…”
Get full text

Coagulation factors and multiple sclerosis : Key factors in the pathogenesis? by Göbel, K, Kleinschnitz, C, Meuth, S G

“…Environmental factors and genetic predisposition influence the individual risk to develop multiple sclerosis (MS). Preclinical results in animal models of MS,…”
Get full text

Immunophenotyping of cerebrospinal fluid cells in ischaemic stroke by Schulte‐Mecklenbeck, A., Kleffner, I., Beuker, C., Wirth, T., Hartwig, M., Schmidt‐Pogoda, A., Klotz, L., Hansen, W., Wiendl, H., Meuth, S. G., Gross, C. C., Minnerup, J.

“…Background and purpose Post‐ischaemic immune cell invasion into the brain is well characterized in animal stroke models and contributes to neuronal damage…”
Get full text

Long-term effects of dalfampridine in patients with multiple sclerosis by Ruck, T, Bittner, S, Simon, O.J, Göbel, K, Wiendl, H, Schilling, M, Meuth, S.G

“…Abstract Background/objective Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired…”
Get full text

Actual medical care situation and therapeutic needs in multiple sclerosis: Impact of the Pharmaceutical Market Restructuring Act (AMNOG) by Bittner, S, Meuth, S G

“…The treatment of patients with multiple sclerosis (MS) is associated with constantly rising costs for the healthcare system and pharmaceuticals constitute 60 %…”
Get full text

Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods by Meuth, S G, Ruck, T, Aktas, O, Hartung, H-P

“…The selective modulation of lymphocyte numbers and function is an attractive concept in the treatment of relapsing-remitting multiple sclerosis (RMS)…”
Get full text

Total atrial conduction time provides novel information in prediction for stroke in patients with sinus rhythm by Bejinariu, A. G., Schilling, M., Müller, P., Clasen, L., Gerguri, S., Angendohr, S., Katsianos, S., Schmidt, J., Brinkmeyer, C., Meuth, S. G., Kelm, M., Makimoto, H.

“…The total atrial conduction time (TACT) measured by echocardiography predicts the risk of atrial fibrillation (AF). This study aimed to investigate whether…”
Get full text

Endothelial Indoleamine-2,3-Dioxygenase-1 is not Critically Involved in Regulating Antitumor Immunity in the Central Nervous System by Abu Hejleh, AP, Huck, K, Jähne, K, Tan, CL, Lanz, TV, Epping, L, Sonner, JK, Meuth, SG, Henneberg, A, Opitz, CA, Herold-Mende, C, Sahm, F, Platten, M, Sahm, K

“…The vascular niche of malignant gliomas is a key compartment that shapes the immunosuppressive brain tumor microenvironment (TME). The blood-brain-barrier…”
Get full text